68
Registered trials
31
Recruiting
34
Completed trials
48
Sponsors
23
Countries
Phase III:
35
Phase II/III:
2
Phase II:
17
Phase I/II:
6
Phase III/IV:
1
Phase IV:
3
Phase I (Other):
2
Phase I (FiH):
2
Oversight events:
1 serious breach
6 temporary halts
2 urgent safety measures
12 unexpected events
1 corrective measure
across 9 trials
View oversight register →
Indications tested
Ovarian cancer
5
Ovarian cancer recurrent
3
Non-small cell lung cancer
3
Breast cancer
3
Fallopian tube cancer
2
Non-small cell lung cancer stage IIIA
2
Bladder cancer
2
Breast cancer metastatic
2
Ovarian cancer metastatic
2
B-cell lymphoma refractory
2
Non-small cell lung cancer stage II
2
Cholangiocarcinoma
2
Sponsors using this IMP
Janssen - Cilag International
7
Merck Sharp & Dohme LLC
6
F. Hoffmann-La Roche AG
5
Genmab A/S
4
Fondazione GONO G.I.
2
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2
Oslo University Hospital HF
2
AGO Research GmbH
1
Alligator Bioscience AB
1
Artios Pharma Limited
1
Asociacion Grupo Tratamiento De Tumores Digestivos
1
Assistance Publique Hopitaux De Paris
1
All trials — page 3
68 totalShowing 49–68 of 68 trials